Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GASC
MCID: GST053
MIFTS: 83

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastric Cancer

About this section

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 56 12 52 73 36 54
Stomach Cancer 12 74 52 73 29 42 15
Stomach Carcinoma 12 52 15 71
Gastric Carcinoma 12 54 17
Malignant Tumor of Lesser Curve of Stomach 12 71
Malignant Neoplasm of Body of Stomach 12 71
Malignant Neoplasm of Stomach 71 32
Stomach Neoplasms 43 71
Malignant Neoplasm of Lesser Curve of Stomach 12
Malignant Tumor of Greater Curve of Stomach 12
Malignant Tumor of Body of Stomach 12
Ca Greater Curvature of Stomach 12
Ca Lesser Curvature - Stomach 12
Gastric Cancer Intestinal 73
Gastric Cancer, Somatic 56
Adult Stomach Carcinoma 52
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 52
Gastric Carcinomas 15
Ca Body - Stomach 12
Gastric Neoplasm 12
Stomach Neoplasm 17
Gastric Cancers 15
Cancer, Gastric 39
Gasc 73

Characteristics:

HPO:

31
gastric cancer:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10534 DOID:5517
OMIM 56 613659
KEGG 36 H00018
MeSH 43 D013274
SNOMED-CT via HPO 68 124975008
UMLS 71 C0024623 C0038356 C0153421 more
Sources

Summaries for Gastric Cancer

About this section
NIH Rare Diseases : 52 Stomach cancer , also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial ." Although the underlying cause of some familial cases is unknown, genetic changes (mutations ) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer , Lynch syndrome , Li-Fraumeni syndrome , familial adenomatous polyposis , and Peutz-Jeghers syndrome . In other families, a cluster of stomach cancers may be due to a combination of gene (s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy , radiation therapy , and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Aspirin and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include stomach, lymph node and liver, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM : 56 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

MedlinePlus : 42 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

KEGG : 36 Gastric cancer (GC) is one of the world's most common cancers. According to Lauren's histological classification gastric cancer is divided into two distinct histological groups - the intestinal and diffuse types. Several genetic changes have been identified in intestinal-type GC. The intestinal metaplasia is characterized by mutations in p53 gene, reduced expression of retinoic acid receptor beta (RAR-beta) and hTERT expression. Gastric adenomas furthermore display mutations in the APC gene, reduced p27 expression and cyclin E amplification. In addition, amplification and overexpression of c-ErbB2, reduced TGF-beta receptor type I (TGFBRI) expression and complete loss of p27 expression are commonly observed in more advanced GC. The main molecular changes observed in diffuse-type GCs include loss of E-cadherin function by mutations in CDH1and amplification of MET and FGFR2F.

UniProtKB/Swiss-Prot : 73 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 74 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Sources

Related Diseases for Gastric Cancer

About this section

Diseases in the Gastric Cancer family:

Hereditary Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1312)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 35.1 PIK3CA MIR27A MIR25 KRAS FGFR2 ERBB2
2 colorectal cancer 34.4 PIK3CA MUTYH MIR34A MIR27A MIR25 MIR222
3 li-fraumeni syndrome 34.1 MUTYH KRAS ERBB2 CTNNB1
4 esophageal cancer 33.9 PIK3CA MIR34A MIR27A MIR21 MIR145 MIR143
5 hepatocellular carcinoma 33.8 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
6 adenocarcinoma 33.8 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
7 small intestine cancer 33.7 MUTYH KRAS ERBB2 CTNNB1
8 pancreatic cancer 33.6 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
9 lung cancer 33.6 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
10 breast cancer 33.6 PIK3CA MIR34A MIR27A MIR222 MIR221 MIR21
11 lung cancer susceptibility 3 33.2 PIK3CA MIR27A MIR21 MIR145 MIR143 MIR106B
12 ovarian cancer 33.2 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
13 prostate cancer 33.2 PIK3CA MIR34A MIR27A MIR25 MIR222 MIR221
14 bladder cancer 33.1 PIK3CA MIR34A MIR222 MIR221 MIR21 MIR145
15 leukemia, chronic lymphocytic 33.1 PIK3CA MIR34A MIR27A MIR221 MIR21 MIR20A
16 adenoma 33.0 PIK3CA MUTYH KRAS CTNNB1 APC
17 signet ring cell adenocarcinoma 33.0 KRAS ERBB2 CTNNB1
18 gastrointestinal system disease 32.9 MIR34A MIR27A MIR25 MIR222 MIR221 MIR21
19 endometrial cancer 32.7 PIK3CA MUTYH MIR34A MIR145 KRAS FGFR2
20 lynch syndrome 32.7 PIK3CA MUTYH KRAS ERBB2 CTNNB1 APC
21 rectum cancer 32.7 MUTYH MIR221 MIR21 MIR20A MIR145 MIR143
22 cervical cancer 32.7 PIK3CA MIR34A MIR21 MIR20A MIR145 MIR143
23 tubular adenocarcinoma 32.7 MIR21 ERBB2 CTNNB1
24 gastrointestinal system cancer 32.6 MIR34A MIR27A MIR25 MIR222 MIR221 MIR21
25 leukemia, acute myeloid 32.6 PIK3CA MIR34A MIR27A MIR222 MIR221 MIR21
26 familial adenomatous polyposis 32.5 MUTYH KRAS CTNNB1 APC
27 cholangiocarcinoma 32.5 PIK3CA MIR21 KRAS FGFR2 ERBB2 CTNNB1
28 renal cell carcinoma, nonpapillary 32.5 PIK3CA MIR34A MIR27A MIR221 MIR21 MIR145
29 myeloma, multiple 32.4 MIR27A MIR25 MIR21 MIR145 MIR106B KRAS
30 papillary adenocarcinoma 32.3 MIR21 KRAS ERBB2
31 melanoma 32.3 PIK3CA MIR34A MIR27A MIR222 MIR221 KRAS
32 pancreatic adenocarcinoma 32.3 PIK3CA MIR221 MIR21 MIR145 KRAS FGFR2
33 lymphoma, non-hodgkin, familial 32.3 PIK3CA MIR34A MIR27A MIR222 MIR21 MIR20A
34 colorectal adenoma 32.2 MUTYH MIR21 KRAS CTNNB1 APC
35 intrahepatic cholangiocarcinoma 32.2 KRAS FGFR2 ERBB2 CTNNB1 APC
36 squamous cell carcinoma, head and neck 32.2 PIK3CA MIR27A MIR221 MIR21 MIR145 MIR143
37 intestinal disease 32.2 MIR34A MIR25 MIR222 MIR221 MIR21 MIR20A
38 pancreatic ductal adenocarcinoma 32.1 MIR222 MIR221 MIR21 MIR145 MIR143 KRAS
39 pancreas disease 32.1 MIR34A MIR27A MIR25 MIR221 MIR21 MIR145
40 in situ carcinoma 32.1 PIK3CA MIR143 ERBB2 CTNNB1
41 nasopharyngeal carcinoma 32.1 PIK3CA MIR21 MIR143 ERBB2 CTNNB1
42 glioma 32.1 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
43 body mass index quantitative trait locus 11 32.0 MIR34A MIR27A MIR222 MIR221 MIR21 MIR143
44 dermatomyositis 32.0 MIR34A MIR222 MIR221 MIR21
45 kidney cancer 32.0 PIK3CA MIR27A MIR21 MIR20A MIR106B
46 arteries, anomalies of 32.0 MIR34A MIR27A MIR25 MIR222 MIR221 MIR21
47 glioblastoma multiforme 31.9 PIK3CA MIR221 MIR21 KRAS ERBB2 CTNNB1
48 diffuse large b-cell lymphoma 31.9 MIR222 MIR221 MIR21 MIR145 MIR143
49 brain cancer 31.9 PIK3CA MIR25 MIR222 MIR21 MIR145 CTNNB1
50 colorectal adenocarcinoma 31.9 KRAS ERBB2 CTNNB1 APC

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer
Sources

Symptoms & Phenotypes for Gastric Cancer

About this section

Human phenotypes related to Gastric Cancer:

31
# Description HPO Frequency HPO Source Accession
1 stomach cancer 31 HP:0012126
2 increased level of l-fucose in urine 31 HP:0410067

Clinical features from OMIM:

613659

UMLS symptoms related to Gastric Cancer:


nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 APC CTNNB1 ERBB2 FGFR2 IRF1 KRAS
Sources

Drugs & Therapeutics for Gastric Cancer

About this section

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 559)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Etomidate Approved Phase 4 33125-97-2 36339 667484
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Azithromycin Approved Phase 4 83905-01-5 447043 55185
8
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Simethicone Approved Phase 4 8050-81-5
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Nicotine Approved Phase 4 54-11-5 942 89594
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
15
Pantoprazole Approved Phase 4 102625-70-7 4679
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Coal tar Approved Phase 4 8007-45-2
18
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
19
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
24
Clarithromycin Approved Phase 4 81103-11-9 84029
25
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
26
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
27
Sodium citrate Approved, Investigational Phase 4 68-04-2
28
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
29
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
30
Ofloxacin Approved Phase 4 82419-36-1 4583
31
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
32
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
33
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
34
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Ecabet Investigational Phase 4 33159-27-2, 86408-72-2 65781
37
Doxifluridine Investigational Phase 4 3094-09-5
38
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
39 Antidotes Phase 4
40 Protective Agents Phase 4
41 Antioxidants Phase 4
42 Platelet Aggregation Inhibitors Phase 4
43 Antipyretics Phase 4
44 Parenteral Nutrition Solutions Phase 4
45 Purinergic P2Y Receptor Antagonists Phase 4
46 Ubiquinone Phase 4
47 Fat Emulsions, Intravenous Phase 4
48 Soybean oil, phospholipid emulsion Phase 4
49 Soy Bean Phase 4
50 Chlorpheniramine, phenylpropanolamine drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 2192)
# Name Status NCT ID Phase Drugs
1 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
2 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
3 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
4 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
5 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
6 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
7 The CHOLEGAS Study: Multicentric Randomized, Double-Blinded, Controlled Trial of Gastrectomy Plus Prophylactic Cholecystectomy Versus Gastrectomy Only, in Adults Submitted to Gastric Cancer Surgery With Curative Intent. Unknown status NCT00757640 Phase 4
8 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
9 Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer Unknown status NCT01766765 Phase 4
10 Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
11 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
12 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
13 A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized，Cross-over Study Unknown status NCT02930616 Phase 4
14 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
15 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
16 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
17 Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment Unknown status NCT03139253 Phase 4 amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
18 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
19 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
20 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
21 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
22 Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial Unknown status NCT01308177 Phase 4 Ecabet
23 Conventional Fluorescein Sodium Dosage o.1ml/kg Compared With a Lower Fluorescein Sodium Dosage o.02ml/kg for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial Unknown status NCT02534818 Phase 4 lower fluorescein sodium dosage 0.02ml/kg;conventional fluorescein sodium dosage 0.1ml/kg
24 Combined Use of Etomidate and Propofol in Painless Gastroscopy, a Multiple Center, Double Blinded, Randomized,Controled Study. Unknown status NCT01913054 Phase 4 Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
25 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
26 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
27 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
28 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
29 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
30 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
31 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
32 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
33 Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
34 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
35 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
36 Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
37 A Study on Efficacy and Safety of Apatinib Mesylate Tablets Combined With Tegio Capsule for First-line Refractory Patients With Late-stage Gastric Cancer Completed NCT04338438 Phase 4 Apatinib Mesylate tablets combined with Tegio capsules
38 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
39 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
40 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
41 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps Completed NCT01471756 Phase 4
42 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
43 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
44 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
45 A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
46 Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea; Open-label, Randomized Controlled Trial Completed NCT03665428 Phase 4 PAMB treatment (modified quadruple therapy);PBMT treatment (bismuth-containing quadruple therapy)
47 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
48 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
49 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
50 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
docetaxel
Floxuridine
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Methotrexate
Methotrexate Sodium

Cochrane evidence based reviews: stomach neoplasms

Sources

Genetic Tests for Gastric Cancer

About this section

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Stomach Cancer 29
Sources

Anatomical Context for Gastric Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

19
Stomach

MalaCards organs/tissues related to Gastric Cancer:

40
Lymph Node, Liver, Testes, Lung, Breast, Colon, T Cells
Sources

Publications for Gastric Cancer

About this section

Articles related to Gastric Cancer:

(show top 50) (show all 39008)
# Title Authors PMID Year
1
Genetic alterations of the MYH gene in gastric cancer. 56 6 61 54
15273732 2004
2
Inactivating mutations of the caspase-10 gene in gastric cancer. 54 56 6 61
11973654 2002
3
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. 61 56 6 54
9679752 1998
4
Genetic alterations of the KLF6 gene in gastric cancer. 56 6 61
15824733 2005
5
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. 6 56 61
1317264 1992
6
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 56 54 61
18488030 2008
7
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. 56 54 61
11419427 2001
8
Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. 56 54 61
8938136 1996
9
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. 54 56 61
8882883 1996
10
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. 61 6
23852704 2014
11
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. 61 46 54
18794849 2008
12
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. 46 54 61
18328430 2008
13
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
14
A full genome scan for gastric cancer. 61 56
15635081 2005
15
Gastric cancer originating from bone marrow-derived cells. 61 56
15567866 2004
16
Genetic susceptibility and gastric cancer risk. 56 61
12115538 2002
17
Red meat, family history, and increased risk of gastric cancer with microsatellite instability. 56 61
11454685 2001
18
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. 54 6
11325814 2001
19
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 56 61
10746728 2000
20
Familial gastric cancer: overview and guidelines for management. 56 61
10593993 1999
21
Familial gastric cancer in the Japanese population is frequently located at the cardiac region. 61 56
10436415 1999
22
Genetic predisposition to gastric cancer. 56 61
10209666 1999
23
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. 61 6
7773929 1995
24
Family history and the risk of stomach and colorectal cancer. 61 56
1606546 1992
25
Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. 56 61
2224804 1990
26
Helicobacter gastritis and intestinal metaplasia in a gastric cancer family. 56 61
1969086 1990
27
The decline in gastric cancer: epidemiology of an unplanned triumph. 56 61
3533579 1986
28
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
29
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
30
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
31
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
32
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
33
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
34
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
35
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. 6
22683711 2012
36
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
37
Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. 6
21079152 2011
38
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. 6
20805368 2010
39
Discordance for Schimmelpenning-Feuerstein-Mims syndrome in monochorionic twins supports the concept of a postzygotic mutation. 6
20949522 2010
40
Epigenetic regulation of miR-196b expression in gastric cancer. 61 46
20662076 2010
41
Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene. 56
20506113 2010
42
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. 46 61
20067763 2010
43
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. 46 61
19153141 2009
44
Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. 61 46
19363643 2009
45
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. 46 54
18789835 2009
46
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. 61 46
18449891 2008
47
After Helicobacter pylori, genetic susceptibility to gastric carcinoma revisited. 56
17991176 2007
48
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
49
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 6
17332249 2007
50
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. 56
16767218 2006
Sources

Variations for Gastric Cancer

About this section

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 92) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FGFR2 NM_022970.3(FGFR2):c.314A>G (p.Tyr105Cys)SNV Pathogenic 449024 rs1434545235 10:123325014-123325014 10:121565500-121565500
2 APC NM_000038.6(APC):c.3867T>A (p.Cys1289Ter)SNV Pathogenic 545962 rs1554085355 5:112175158-112175158 5:112839461-112839461
3 FGFR2 NM_000141.5(FGFR2):c.1150G>A (p.Gly384Arg)SNV Pathogenic 478046 rs1554927408 10:123274768-123274768 10:121515254-121515254
4 APC NM_000038.6(APC):c.3359G>A (p.Gly1120Glu)SNV Pathogenic 802 rs28933379 5:112174650-112174650 5:112838953-112838953
5 APC NM_000038.6(APC):c.3199C>T (p.Gln1067Ter)SNV Pathogenic 803 rs137854571 5:112174490-112174490 5:112838793-112838793
6 APC NM_000038.6(APC):c.1660C>T (p.Arg554Ter)SNV Pathogenic 807 rs137854573 5:112164586-112164586 5:112828889-112828889
7 APC NM_000038.6(APC):c.2805C>A (p.Tyr935Ter)SNV Pathogenic 810 rs137854575 5:112174096-112174096 5:112838399-112838399
8 MUTYH NM_012222.2(MUTYH):c.1204C>T (p.Pro402Ser)SNV Pathogenic 5298 rs121908382 1:45797202-45797202 1:45331530-45331530
9 MUTYH NM_012222.2(MUTYH):c.1232A>G (p.Gln411Arg)SNV Pathogenic 5299 rs121908383 1:45797174-45797174 1:45331502-45331502
10 KLF6 NM_001300.6(KLF6):c.465C>A (p.Ser155Arg)SNV Pathogenic 7574 rs121909144 10:3824044-3824044 10:3781852-3781852
11 CASP10 NM_001230.5(CASP10):c.685-2146C>TSNV Pathogenic 7766 rs121909775 2:202070652-202070652 2:201205929-201205929
12 KRAS NM_033360.4(KRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 12582 rs121913529 12:25398284-25398284 12:25245350-25245350
13 KRAS NM_033360.4(KRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12584 rs121913530 12:25398285-25398285 12:25245351-25245351
14 FGFR2 NM_000141.5(FGFR2):c.1025G>A (p.Cys342Tyr)SNV Pathogenic 13263 rs121918487 10:123276892-123276892 10:121517378-121517378
15 FGFR2 NM_000141.5(FGFR2):c.1032G>A (p.Ala344=)SNV Pathogenic 13268 rs121918491 10:123276885-123276885 10:121517371-121517371
16 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp)SNV Pathogenic 13272 rs79184941 10:123279677-123279677 10:121520163-121520163
17 FGFR2 NM_000141.5(FGFR2):c.758C>G (p.Pro253Arg)SNV Pathogenic 13273 rs77543610 10:123279674-123279674 10:121520160-121520160
18 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys)SNV Pathogenic 13277 rs121913478 10:123274794-123274794 10:121515280-121515280
19 FGFR2 NM_000141.5(FGFR2):c.799T>C (p.Ser267Pro)SNV Pathogenic 13290 rs121918505 10:123279633-123279633 10:121520119-121520119
20 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
21 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
22 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs)duplication Pathogenic 13658 rs587776802 3:178952146-178952147 3:179234358-179234359
23 IRF1 NM_002198.3(IRF1):c.22A>T (p.Met8Leu)SNV Pathogenic 14720 rs121912469 5:131825149-131825149 5:132489457-132489457
24 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
25 APC NM_000038.6(APC):c.694C>T (p.Arg232Ter)SNV Pathogenic 42248 rs397515734 5:112128191-112128191 5:112792494-112792494
26 MUTYH NM_001128425.1(MUTYH):c.55C>T (p.Arg19Ter)SNV Pathogenic 127845 rs587780088 1:45800165-45800165 1:45334493-45334493
27 APC NM_000038.6(APC):c.637C>T (p.Arg213Ter)SNV Pathogenic 140952 rs587781392 5:112116592-112116592 5:112780895-112780895
28 APC NM_000038.6(APC):c.646C>T (p.Arg216Ter)SNV Pathogenic 127312 rs62619935 5:112128143-112128143 5:112792446-112792446
29 APC NM_000038.6(APC):c.847C>T (p.Arg283Ter)SNV Pathogenic 184999 rs786201856 5:112151204-112151204 5:112815507-112815507
30 MUTYH NM_001048171.1(MUTYH):c.692G>A (p.Arg231His)SNV Pathogenic/Likely pathogenic 140877 rs140342925 1:45798117-45798117 1:45332445-45332445
31 MUTYH NM_001048174.2(MUTYH):c.1103-2A>GSNV Pathogenic/Likely pathogenic 141282 rs587781628 1:45797230-45797230 1:45331558-45331558
32 MUTYH NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys)SNV Pathogenic/Likely pathogenic 5293 rs34612342 1:45798475-45798475 1:45332803-45332803
33 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp)SNV Pathogenic/Likely pathogenic 5294 rs36053993 1:45797228-45797228 1:45331556-45331556
34 ERBB2 NM_004448.3(ERBB2):c.2326G>A (p.Gly776Ser)SNV Pathogenic/Likely pathogenic 13879 rs28933369 17:37880997-37880997 17:39724744-39724744
35 APC NM_000038.6(APC):c.70C>T (p.Arg24Ter)SNV Pathogenic/Likely pathogenic 184702 rs145945630 5:112090657-112090657 5:112754960-112754960
36 APC NM_000038.6(APC):c.1312+3A>GSNV Pathogenic/Likely pathogenic 217924 rs863225311 5:112155044-112155044 5:112819347-112819347
37 MUTYH NM_001048174.2(MUTYH):c.305-1G>CSNV Pathogenic/Likely pathogenic 234229 rs372267274 1:45798843-45798843 1:45333171-45333171
38 APC NM_000038.6(APC):c.933+1G>ASNV Pathogenic/Likely pathogenic 233970 rs876660765 5:112151291-112151291 5:112815594-112815594
39 FGFR2 NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu)SNV Pathogenic/Likely pathogenic 374817 rs1057519044 10:123276904-123276904 10:121517390-121517390
40 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr)SNV Pathogenic/Likely pathogenic 375894 rs121913403 3:41266113-41266113 3:41224622-41224622
41 ERBB3 NM_001982.3(ERBB3):c.850G>A (p.Gly284Arg)SNV Likely pathogenic 376167 rs1057519803 12:56481922-56481922 12:56088138-56088138
42 NRAS NM_002524.5(NRAS):c.37G>A (p.Gly13Ser)SNV Likely pathogenic 376221 rs121434595 1:115258745-115258745 1:114716124-114716124
43 CTNNB1 NM_001904.4(CTNNB1):c.109T>C (p.Ser37Pro)SNV Likely pathogenic 376234 rs121913228 3:41266112-41266112 3:41224621-41224621
44 CTNNB1 NM_001904.4(CTNNB1):c.118A>G (p.Thr40Ala)SNV Likely pathogenic 376237 rs1057519836 3:41266121-41266121 3:41224630-41224630
45 MTHFR NM_005957.5(MTHFR):c.665C>T (p.Ala222Val)SNV drug response 3520 rs1801133 1:11856378-11856378 1:11796321-11796321
46 MUTYH NM_012222.2(MUTYH):c.1220_1221dup (p.Pro408fs)duplication Likely pathogenic 417906 rs1553125914 1:45797184-45797185 1:45331512-45331513
47 APC NM_000038.6(APC):c.8389A>G (p.Ser2797Gly)SNV Conflicting interpretations of pathogenicity 141436 rs147287751 5:112179680-112179680 5:112843983-112843983
48 APC NM_000038.6(APC):c.6639G>A (p.Met2213Ile)SNV Conflicting interpretations of pathogenicity 141618 rs35540155 5:112177930-112177930 5:112842233-112842233
49 APC NM_000038.6(APC):c.5363G>A (p.Arg1788His)SNV Conflicting interpretations of pathogenicity 92348 rs201472075 5:112176654-112176654 5:112840957-112840957
50 MUTYH NM_001048171.1(MUTYH):c.530G>A (p.Arg177Gln)SNV Conflicting interpretations of pathogenicity 127846 rs369677603 1:45798439-45798439 1:45332767-45332767

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

73 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs140029598
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

Cosmic variations for Gastric Cancer:

9 (show top 50) (show all 46209)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 66
2 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 66
3 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 66
4 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 66
5 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 66
6 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 66
7 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 66
8 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 66
9 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 66
10 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 66
11 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 66
12 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 66
13 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 66
14 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 66
15 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 66
16 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 66
17 COSM101978786 XPO1 stomach,NS,carcinoma,adenocarcinoma c.1249C>T p.R417C 2:61493050-61493050 66
18 COSM101977484 XPO1 stomach,NS,carcinoma,adenocarcinoma c.382G>A p.G128R 2:61502022-61502022 66
19 COSM101978758 XPO1 stomach,NS,carcinoma,adenocarcinoma c.781C>T p.R261* 2:61496986-61496986 66
20 COSM101978769 XPO1 stomach,NS,carcinoma,adenocarcinoma c.3154C>T p.R1052C 2:61478882-61478882 66
21 COSM91376043 WT1 stomach,NS,carcinoma,adenocarcinoma c.1399A>T p.K467* 11:32392005-32392005 66
22 COSM91380538 WT1 stomach,NS,carcinoma,adenocarcinoma c.326C>T p.A109V 11:32435020-32435020 66
23 COSM91376032 WT1 stomach,NS,carcinoma,adenocarcinoma c.1403C>T p.T468I 11:32392001-32392001 66
24 COSM91376050 WT1 stomach,NS,carcinoma,adenocarcinoma c.1392C>G p.D464E 11:32392012-32392012 66
25 COSM91376024 WT1 stomach,NS,carcinoma,adenocarcinoma c.1405C>T p.H469Y 11:32391999-32391999 66
26 COSM91376062 WT1 stomach,NS,carcinoma,adenocarcinoma c.1376A>T p.K459M 11:32392028-32392028 66
27 COSM91373352 WT1 stomach,NS,carcinoma,adenocarcinoma c.1165C>T p.R389C 11:32396341-32396341 66
28 COSM91376084 WT1 stomach,NS,carcinoma,adenocarcinoma c.1403C>G p.T468S 11:32392001-32392001 66
29 COSM91365177 WT1 stomach,NS,carcinoma,adenocarcinoma c.1073C>T p.T358M 11:32399973-32399973 66
30 COSM91365621 WT1 stomach,NS,carcinoma,adenocarcinoma c.1502G>A p.R501H 11:32389110-32389110 66
31 COSM91376004 WT1 stomach,NS,carcinoma,adenocarcinoma c.991G>A p.G331R 11:32416500-32416500 66
32 COSM101789719 WEE2 stomach,NS,carcinoma,adenocarcinoma c.996C>G p.N332K 7:141723249-141723249 66
33 COSM88718278 USH2A stomach,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 1:215728169-215728169 66
34 COSM88706690 USH2A stomach,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 1:215878834-215878834 66
35 COSM88730784 USH2A stomach,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 1:215728281-215728281 66
36 COSM88763597 USH2A stomach,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 1:216422197-216422197 66
37 COSM88760265 USH2A stomach,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 1:215728362-215728362 66
38 COSM127065236 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5261G>A p.R1754Q 8:102285736-102285736 66
39 COSM127056711 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5561G>A p.R1854H 8:102285262-102285262 66
40 COSM85199244 U2AF1 stomach,NS,carcinoma,adenocarcinoma c.68A>G p.K23R 21:43104379-43104379 66
41 COSM140496615 TTN stomach,NS,carcinoma,adenocarcinoma c.72860T>C p.L24287P 2:178573272-178573272 66
42 COSM140712014 TTN stomach,NS,carcinoma,adenocarcinoma c.53507G>A p.R17836H 2:178607095-178607095 66
43 COSM140869246 TTN stomach,NS,carcinoma,adenocarcinoma c.75574G>C p.E25192Q 2:178570558-178570558 66
44 COSM140849450 TTN stomach,NS,carcinoma,adenocarcinoma c.76779T>A p.F25593L 2:178569353-178569353 66
45 COSM140492669 TTN stomach,NS,carcinoma,adenocarcinoma c.72534A>C p.Q24178H 2:178573598-178573598 66
46 COSM140722447 TTN stomach,NS,carcinoma,adenocarcinoma c.70474T>C p.C23492R 2:178575658-178575658 66
47 COSM140601461 TTN stomach,NS,carcinoma,adenocarcinoma c.63361G>T p.A21121S 2:178588046-178588046 66
48 COSM140872494 TTN stomach,NS,carcinoma,adenocarcinoma c.51827A>G p.Y17276C 2:178609483-178609483 66
49 COSM140457071 TTN stomach,NS,carcinoma,adenocarcinoma c.4049G>A p.R1350H 2:178779033-178779033 66
50 COSM140494721 TTN stomach,NS,carcinoma,adenocarcinoma c.102154C>T p.R34052W 2:178534461-178534461 66

Copy number variations for Gastric Cancer from CNVD:

7 (show top 50) (show all 694)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13401 1 1 2300000 Gain SLC35E2 Gastric cancer
2 13782 1 1 39600000 Gain LCK Gastric cancer
3 13783 1 1 39600000 Gain MDS2 Gastric cancer
4 13784 1 1 39600000 Gain PAX7 Gastric cancer
5 13785 1 1 39600000 Gain PRDM16 Gastric cancer
6 13786 1 1 39600000 Gain RPL22 Gastric cancer
7 13787 1 1 39600000 Gain SDHB Gastric cancer
8 13988 1 102200000 107200000 Loss AMY1A Gastric cancer
9 13989 1 102200000 107200000 Loss AMY2A Gastric cancer
10 19425 1 150222010 150233338 Amplification S100A10 Gastric cancer
11 22648 1 168031174 168088853 Amplification C1orf112 Gastric cancer
12 22794 1 168899937 168975165 Amplification PRRX1 Gastric cancer
13 24343 1 178867796 179122103 Amplification XPR1 Gastric cancer
14 25997 1 195319997 195382287 Amplification ASPM Gastric cancer
15 26293 1 198787930 198856485 Amplification KIF14 Gastric cancer
16 27965 1 216525252 216577948 Amplification RRP15 Gastric cancer
17 28583 1 223655827 223682407 Amplification LBR Gastric cancer
18 29302 1 2300000 5400000 Gain TP73 Gastric cancer
19 29303 1 2300000 5400000 Gain WDR8 Gastric cancer
20 29725 1 234780594 234834437 Amplification HEATR1 Gastric cancer
21 30108 1 240078158 240119671 Amplification EXO1 Gastric cancer
22 30593 1 244770489 244796186 Amplification TFB2M Gastric cancer
23 37702 1 938709 939782 Copy number G1P2 Gastric cancer
24 37787 1 94700000 99700000 Loss DPYD Gastric cancer
25 38140 10 1 135006516 Loss Gastric cancer
26 40043 10 123336181 123337713 Amplification FGFR2 Gastric cancer
27 40401 10 127500000 130600000 Gain Gastric cancer
28 41839 10 24600000 135534747 Loss Gastric cancer
29 45622 10 73000000 81800000 Amplification PSAP Gastric cancer
30 48318 11 1 135006516 Gain Gastric cancer
31 49710 11 110400000 130800000 Gain Gastric cancer
32 49997 11 112500000 130800000 Gain Gastric cancer
33 53360 11 2800000 10700000 Gain CDKN1C Gastric cancer
34 53361 8 145646122 145661839 Gain CYHR1 Gastric cancer
35 53362 8 145669924 145672526 Gain FOXH1 Gastric cancer
36 53363 11 2800000 10700000 Gain KCNQ1 Gastric cancer
37 53364 11 2800000 10700000 Gain KCNQ1DN Gastric cancer
38 53365 8 145662545 145670307 Gain KIFC2 Gastric cancer
39 53366 11 2800000 10700000 Gain SLC22A18 Gastric cancer
40 53367 11 2800000 10700000 Gain SLC22A1LS Gastric cancer
41 54234 11 40200000 42900000 Amplification LRRC4C Gastric cancer
42 56156 11 57265297 57267459 Copy number SELH Gastric cancer
43 56517 11 59900000 61700000 Gain PGA5 Gastric cancer
44 58503 11 68100000 70400000 Amplification CCND1 Gastric cancer
45 58504 11 68100000 70400000 Amplification FGF3 Gastric cancer
46 58651 11 69161019 69306967 Amplification CCND1 Gastric cancer
47 58653 11 69161019 69306967 Amplification FGF19 Gastric cancer
48 58655 11 69161019 69306967 Amplification FGF4 Gastric cancer
49 58657 11 69161019 69306967 Amplification ORAOV1 Gastric cancer
50 59248 11 73719009 73787150 Amplification PGM2L1 Gastric cancer
Sources

Expression for Gastric Cancer

About this section
Search GEO for disease gene expression data for Gastric Cancer.
Sources

Pathways for Gastric Cancer

About this section

Pathways related to Gastric Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Gastric cancer hsa05226

Pathways related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 36
Show member pathways
 12.84 PIK3CA KRAS IRF1 FGFR2 ERBB2 CTNNB1
2
Endometrial cancer 36
Show member pathways
 12.77 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
3
Pathways in cancer 36
12.71 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
4
Gastric cancer 36
Show member pathways
 12.62 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
5
Development HGF signaling pathway 22
Show member pathways
 12.6 PIK3CA KRAS ERBB2 CTNNB1 APC
6
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.4 PIK3CA KRAS FGFR2 ERBB2 APC
7
VEGF Signaling 66
Show member pathways
 12.39 PIK3CA KRAS FGFR2 CTNNB1 CASP10
8
Prolactin Signaling Pathway 36 1
Show member pathways
 12.36 PIK3CA KRAS IRF1 ERBB2
9
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.27 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
10
DNA Damage Response